Orforglipron vs Humanin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronAnti-Aging & Longevity
Humanin- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- Half-Life
- ~12 hours (once-daily oral dosing)
- ~4–8 hours (HNG)
- Admin Route
- Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 2–8 mg
- Frequency
- Once daily
- 3–5 times per week
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Injection site irritation
- Limited human safety data available
- Stacks With
- —
- —